Cyclacel Pharmaceuticals ... (CYCC)
Cyclacel Pharmaceuticals Statistics
Share Statistics
Cyclacel Pharmaceuticals has 207.34M shares outstanding. The number of shares has increased by 14069.46% in one year.
| Shares Outstanding | 207.34M |
| Shares Change (YoY) | 14069.46% |
| Shares Change (QoQ) | 3197.74% |
| Owned by Institutions (%) | 0.23% |
| Shares Floating | 12.71M |
| Failed to Deliver (FTD) Shares | 3.21K |
| FTD / Avg. Volume | 0.61% |
Short Selling Information
The latest short interest is 27.62K, so 0.2% of the outstanding shares have been sold short.
| Short Interest | 27.62K |
| Short % of Shares Out | 0.2% |
| Short % of Float | 0.25% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.07 and the forward PE ratio is -0.25. Cyclacel Pharmaceuticals's PEG ratio is 0.
| PE Ratio | -0.07 |
| Forward PE | -0.25 |
| PS Ratio | 18.82 |
| Forward PS | 0.5 |
| PB Ratio | -0.37 |
| P/FCF Ratio | -0.1 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Cyclacel Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.59, with a Debt / Equity ratio of 0.
| Current Ratio | 0.59 |
| Quick Ratio | 0.59 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $3.58K |
| Profits Per Employee | $-934.33K |
| Employee Count | 12 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -782K |
| Effective Tax Rate | 6.52% |
Stock Price Statistics
The stock price has increased by -85.85% in the last 52 weeks. The beta is 0.15, so Cyclacel Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.15 |
| 52-Week Price Change | -85.85% |
| 50-Day Moving Average | 0.29 |
| 200-Day Moving Average | 0.68 |
| Relative Strength Index (RSI) | 62.3 |
| Average Volume (20 Days) | 522.54K |
Income Statement
In the last 12 months, Cyclacel Pharmaceuticals had revenue of 43K and earned -11.21M in profits. Earnings per share was -5.21.
| Revenue | 43K |
| Gross Profit | 43K |
| Operating Income | -12M |
| Net Income | -11.21M |
| EBITDA | -12M |
| EBIT | -12M |
| Earnings Per Share (EPS) | -5.21 |
Balance Sheet
The company has 3.14M in cash and 0 in debt, giving a net cash position of 3.14M.
| Cash & Cash Equivalents | 3.14M |
| Total Debt | 0 |
| Net Cash | 3.14M |
| Retained Earnings | -439.49M |
| Total Assets | 4.09M |
| Working Capital | -2.59M |
Cash Flow
In the last 12 months, operating cash flow was -7.99M and capital expenditures 0, giving a free cash flow of -7.99M.
| Operating Cash Flow | -7.99M |
| Capital Expenditures | 0 |
| Free Cash Flow | -7.99M |
| FCF Per Share | -3.71 |
Margins
Gross margin is 100%, with operating and profit margins of -27916.28% and -26074.42%.
| Gross Margin | 100% |
| Operating Margin | -27916.28% |
| Pretax Margin | -27893.02% |
| Profit Margin | -26074.42% |
| EBITDA Margin | -27902.33% |
| EBIT Margin | -27916.28% |
| FCF Margin | -18581.4% |
Dividends & Yields
CYCC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CYCC is $11, which is 3566.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $11 |
| Price Target Difference | 3566.7% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Dec 18, 2023. It was a backward split with a ratio of 1:15.
| Last Split Date | Dec 18, 2023 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -155.1 |
| Piotroski F-Score | 1 |